Royal Bank of Canada
CMMB

Royal Bank of Canada’s Chemomab Therapeutics CMMB Stock Holding History

Royal Bank of Canada’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62
Closed – – 7136
2023
Q2 		$0 Hold
62
– – ﹤0.01% 7301
2023
Q1 		$0 Hold
62
– – ﹤0.01% 7114
2022
Q4 		$1K Hold
62
– – ﹤0.01% 7012
2022
Q3 		$1K Hold
62
– – ﹤0.01% 7166
2022
Q2 		$1K Sell
62
-3
-5% -$42 ﹤0.01% 7099
2022
Q1 		$1K Buy
+65
New +$1.28K ﹤0.01% 7582

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
MWA
Moser Wealth Advisors Bellevue, Washington $208M AUM 14.21% 1-Year Est. Return

Royal Bank of Canada's CMMB Position: Q3 2023 in Review

Royal Bank of Canada sold out of Chemomab Therapeutics (CMMB) in Q3 2023, closing a stake of 62 shares.

Royal Bank of Canada first reported a position in CMMB in Q1 2022 and held it in 6 quarters. The position peaked at $1K in Q4 2022. 12 funds tracked by Wall St. Rank hold CMMB as of Q3 2023.

  • Royal Bank of Canada reported no remaining Chemomab Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 62 Chemomab Therapeutics shares in Q3 2023.
  • Royal Bank of Canada first reported a position in Chemomab Therapeutics in Q1 2022 and held it in 6 quarters.
  • Royal Bank of Canada's Chemomab Therapeutics position peaked at $1K in Q4 2022.
  • 12 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2023.

Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.